Cost-efficacy comparison of biological therapies for patients with moderate to severe psoriasis in Japan

Journal of Dermatological Treatment

Volumn 24, Issue 5, 2013, Pages 351-355

  Igarashi, Atsuyuki ^a   Kuwabara, Hiroyo ^b   Fahrbach, Kyle ^c   Schenkel, Brad ^d  

^a Kanto Teishin Hospital   (Japan)

^b Janssen Pharmaceutical KK   (Japan)

^c UNITED BIOSOURCE CORPORATION   (United States)

^d Janssen Scientific Affairs LLC   (United States)

Author keywords

Adalimumab; Infliximab; Mixed treatment comparison; Ustekinumab

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; USTEKINUMAB;

ADULT; ARTICLE; BIOLOGICAL THERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL PRODUCTS; BIOLOGICAL THERAPY; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84883589123     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2012.697111     Document Type: Article

References (28)

1. Lebwohl M. Psoriasis. Lancet. 2003;361:1197-1204
2. Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34: 314-321
3. Tsai TF, Wang TS, Hung ST, Tsai PI, Schenkel B, Zhang M, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci. 2011;63:40-46
4. TakahashiH, Takahashi I, TsujiH, IbeM, KinouchiM, Hashimoto Y, et al. Analysis of psoriatic patients registered in Asahikawa Medical College Hospital from 1983 to 2007. J Dermatol. 2009;36:632-637
5. Kawada A, Tezuka T, Nakamizo Y, Kimura H, Nakagawa H, Ohkido M, et al. A survey of psoriasis patients in Japan from 1982 to 2001. J Dermatol Sci. 2003;31:59-64
6. Zachariae R, Zachariae H, Blomqvist K, Davidsson S, Molin L, Mork C, et al. Epidemiology and health service research quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol. 2002;146:1006-1016
7. Saurat JH, Guerin A, Yu AP, Latremouille-Viau D, Wu EQ, Gupta SR, et al. High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: Associated clinical and economic outcomes in real-world practice. Dermatol. 2010;220:128-137
8. Beyer V, Wolverton SE. Recent trends in systemic psoriasis treatment costs. Arch Dermatol. 2010;146:46-54
9. Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. Costeffectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol. 2008;58:125-135
10. Schmitt-Rau K, Rosenbach T, Radtke MA, Augustin M. Costeffectiveness of biological therapy in remission induction of moderate to severe plaque psoriasis. Dermatol. 2010;221:236-242
11. Sizto S, Bansback N, Feldman SR, Willian MK, Anis AH. Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol. 2009;160:1264-1272
12. Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman SR. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. J Dermatolog Treat. 2011;22:65-74
13. Martin S, Feldman SR, Augustin M, Szapary P, Schenkel B. Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis. J Dermatolog Treat. 2011;22:138-143
14. Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, et al. Etanercept and efalizumab for the treatment of psoriasis : A systematic review. Health Technol Assess. 2006;10:1-233
15. Reich K, Burden AD, Eaton JN, Hawkins NS. Efficacy of biologics in the treatment of moderate to severe psoriasis. A network meta-analysis of randomised controlled trials. Br J Dermatol. 2011;166:179-188
16. Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, et al. Interpreting indirect treatment comparisons and network metaanalysis for health-care decision making: Report of the ISPOR task force on indirect treatment comparisons good research practices: Part 1. Value Health. 2011;14:417-428
17. Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: Report of the ISPOR task force on indirect treatment comparisons good research practices-Part 2. Value Health. 2011;14:429-437
18. Lebwohl M, Yeilding N, Szapary P, Wang U, Li S, Zhu Y, et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rational for dosing recommendations. J Am Acad Dermatol. 2010;63:571-579
19. Asahina A, Nakagawa H, Etoh T, Ohtsuki M. Adalimumab M04-688 Study Group. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a phase II/III randomized controlled study. J Dermatol. 2010;37:299-310
20. Torii H, Nakagawa H. Japanese Infliximab Study Investigators. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci. 2010;59:40-49
21. Igarashi A, Kato T, Kato M, Song M, Nakagawa H. Japanese Ustekinumab Study Group. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial. J Dermatol. 2012;39:242-252
22. Ministry of Health, Labour and Welfare, National Nutrition Survey. 2008. Available from http://www.mhlw.go.jp/bunya/kenkou/eiyou/dl/ h20-houkoku-03.pdf. cited 5 January 2011
23. Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomized double blind multicentre trial. BMJ. 2010;340:C147
24. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106-115
25. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, et al. Efficady and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158: 558-566
26. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. Lancet. 2005;366: 1367-1374
27. Pearce DJ, Singh S, Balkrishnan R, Kulkarni A, Fleischer AB, Feldman SR. The negative impact of psoriasis on the workplace. J Dermatolog Treat. 2006;17:24-28
28. Reich K, Schenkel B, Zhao N, Szapary P, Augustin M, Bourcier M, et al. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: Results from PHOENIX 2. J Dermatolog Treat. 2011;22: 337-347